In a study from our group, which evaluated 197 patients with single hormone receptor-positive BC (121 ER+/PR− and 76 ER−/PR+), ER−/PR+ BCs were characterized by a significantly higher number of sTILs than ER+/PR− BCs. This evidence concerns the gene ESR1 and breast cancer.